Premium
Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy
Author(s) -
Sethi Roshan,
Kozin Elliott,
Remenschneider Aaron,
Meier Josh,
VanderLaan Paul,
Faquin William,
Deschler Daniel,
Frankenthaler Robert
Publication year - 2014
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.24254
Subject(s) - acinic cell carcinoma , malignancy , mucoepidermoid carcinoma , adenocarcinoma , carcinoma , pathology , mammary gland , salivary gland , breast carcinoma , metastasis , immunohistochemistry , medicine , cancer , oncology , breast cancer
Objectives/Hypothesis To review the known histopathologic findings and clinical behavior of mammary analogue secretory carcinoma (MASC). Data Sources PubMed. Review Methods Literature search using the terms “Mammary analogue secretory carcinoma,” “Mammary analog secretory carcinoma,” and “MASC” to identify all relevant publications. Results MASC is an unusual and rare malignant salivary gland tumor first described in 2010. It shares histologic, immunohistochemical, and genetic features with secretory carcinoma of the breast. The clinical behavior of MASC ranges from slowly growing tumors that infrequently recur after surgical resection to aggressive tumors that cause widespread metastasis and death. Many cases of MASC were discovered in archived cases previously classified as acinic cell carcinoma, mucoepidermoid carcinoma, and adenocarcinoma not otherwise specified. Conclusion MASC is a newly recognized variant of salivary gland malignancy. Further research is needed to better delineate its overall prevalence and to define an appropriate treatment algorithm for this new clinical entity. Level of Evidence NA. Laryngoscope , 124:188–195, 2014